New ‘gene silencer’ drug dramatically reduces cholesterol

A new “gene silencer” drug could reduce cholesterol by more than 50% among patients at risk of cardiovascular disease, researchers say.

Scientists have hailed the results of ORION-1, the largest trial yet into the safety and effectiveness of the drugs known as inclisiran, as “hugely exciting”.

Researchers from Imperial College London led the phase 2 clinical trial involving RNA interference (RNAi) therapy – a technique that switches off one of the genes responsible for elevated cholesterol levels.

Writing in the New England Journal of Medicine, they say that treatment could be delivered twice a year with or without statins and that inclisiran could help to reduce the risk of heart attacks and stroke associated with high cholesterol.

Professor Kausik Ray, lead author of the study from the School of Public Health at Imperial, said: “These initial results are hugely exciting for patients and clinicians.

“We appear to have found a versatile, easy-to-take, safe, treatment that provides sustained lowering of cholesterol levels and is therefore likely to reduce the risk of cardiovascular disease, heart attacks, and stroke. These reductions are over and above what can be already be achieved with statins alone or statins plus ezetemibe.”

Many patients are unable to tolerate the highest doses of statins, the standard treatment for high cholesterol, and cholesterol levels can also remain high, even if they take the maximum dose.

But this trial, which was presented the findings at the American College of Cardiology’s (ACC) 66th Annual Scientific Session in Washington, has demonstrated that injecting inclisiran reduces cholesterol and that it can be prescribed on its own or with statins, depending on a patient’s needs.

A total of 497 people from Canada, USA, Germany, Netherlands and the UK were enrolled on to the trial. All had high cholesterol and had a high risk of cardiovascular disease, with almost three quarters prescribed statins, while 31% took ezetimibe.

Participants were excluded if they were taking monoclonal antibodies for cholesterol lowering.

They were given different doses of inclisiran or placebo via subcutaneous injection, either via a single dose, or via a dose on day one and another at three months. They were followed up regularly for eight months and tested for blood cholesterol and side effects.

The research team found participants’ LDL cholesterol levels reduced by up to 51%, just one month after receiving a single treatment of inclisiran.

At six months, the participants on a single dose of 300mg saw their cholesterol levels drop by 42%. Conversely, patients in the matched placebo group saw their cholesterol rise by 2%.

Participants who had two doses of 300mg saw their cholesterol levels drop by up to 53% at six months – 48% achieved cholesterol levels below 50 mL/dL.

Cholesterol levels stayed lower for at least eight months among all patients and no additional side effects were reported.

The authors say that because inclisiran acts on a different biological pathway from statins, best results are likely to be yielded if the two drugs are combined.

The next step is to conduct an extended study, using more patients and for a longer period of time, to determine if these cholesterol level reductions lead to fewer heart attacks and strokes.

Ray K K, Landmesser U, Lawrence A L et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New England Journal of Medicine. 17 March 2017. DOI: 10.1056/NEJMoa1615758 www.nejm.org/doi/full/10.1056/NEJMoa1615758

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index